Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2016.10.003
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Elsevier BV